skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 1,691  for All Library Resources

Results 1 2 3 4 5 next page
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Clinical Trial: SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
Material Type:
Newsletter Article
Add to My Research

Clinical Trial: SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

US Fed News Service, Including US State News, 2024

Copyright HT Digital Streams Limited Jun 4, 2024

Digital Resources/Online E-Resources

2
The Christ Hospital Health Network Implants First-of-Its-Kind Device to Repair Leaky Heart Valve
Material Type:
Newsletter Article
Add to My Research

The Christ Hospital Health Network Implants First-of-Its-Kind Device to Repair Leaky Heart Valve

News Bites - Private Companies, 2024

Copyright News Bites Pty Ltd Jun 4, 2024

Digital Resources/Online E-Resources

3
TELA Bio Appoints Jeffrey Blizard to its Board of Directors
Material Type:
Newsletter Article
Add to My Research

TELA Bio Appoints Jeffrey Blizard to its Board of Directors

NASDAQ OMX's News Release Distribution Channel, 2024

GlobeNewswire, Inc.

Digital Resources/Online E-Resources

4
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Material Type:
Newsletter Article
Add to My Research

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NASDAQ OMX's News Release Distribution Channel, 2024

GlobeNewswire, Inc.

Digital Resources/Online E-Resources

5
Ventricular Assist Device (VAD) Market Expected to Reach USD 3.08 Bn by 2032
Material Type:
Newsletter Article
Add to My Research

Ventricular Assist Device (VAD) Market Expected to Reach USD 3.08 Bn by 2032

Financial Services Monitor Worldwide, 2024

2022 Global Data Point. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Digital Resources/Online E-Resources

6
AstraZeneca: Tagrisso Reduced the Risk of Disease Progression or Death by 84% in Patients With Unresectable, Stage III EGFR-Mutated Lung Cancer vs. Placebo in LAURA Phase III Trial
Material Type:
Newsletter Article
Add to My Research

AstraZeneca: Tagrisso Reduced the Risk of Disease Progression or Death by 84% in Patients With Unresectable, Stage III EGFR-Mutated Lung Cancer vs. Placebo in LAURA Phase III Trial

Targeted News Service, 2024

Targeted News Service

Digital Resources/Online E-Resources

7
Journal of the American College of Cardiology Issues Research Articles in June 11, 2024 Edition
Material Type:
Newsletter Article
Add to My Research

Journal of the American College of Cardiology Issues Research Articles in June 11, 2024 Edition

Targeted News Service, 2024

Targeted News Service

Digital Resources/Online E-Resources

8
AstraZeneca (AZN: GBX12,418.0) increases GBX72.0, lifts 3.2% for week; +GBX72 [0.6%] Vol Index 2.3 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

AstraZeneca (AZN: GBX12,418.0) increases GBX72.0, lifts 3.2% for week; +GBX72 [0.6%] Vol Index 2.3 [1 is avg]

Company Data Report, 2024

Copyright News Bites Pty Ltd Jun 4, 2024

Digital Resources/Online E-Resources

9
AstraZeneca (AZN: GBX12,418.0) strengthens above moving average price; +GBX72 [0.6%] Vol Index 2.3 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

AstraZeneca (AZN: GBX12,418.0) strengthens above moving average price; +GBX72 [0.6%] Vol Index 2.3 [1 is avg]

Company Data Report, 2024

Copyright News Bites Pty Ltd Jun 4, 2024

Digital Resources/Online E-Resources

10
INTERNATIONAL PATENT: THE CHILDREN'S MEDICAL CENTER CORPORATION FILES APPLICATION FOR "METHODS OF TREATING HEART FAILURE"
Material Type:
Newsletter Article
Add to My Research

INTERNATIONAL PATENT: THE CHILDREN'S MEDICAL CENTER CORPORATION FILES APPLICATION FOR "METHODS OF TREATING HEART FAILURE"

US Fed News Service, Including US State News, 2024

Copyright HT Digital Streams Limited Jun 4, 2024

Digital Resources/Online E-Resources

11
AstraZeneca (AZN: GBX12,420.0) strengthens above moving average price; +GBX74 [0.6%]
Material Type:
Newsletter Article
Add to My Research

AstraZeneca (AZN: GBX12,420.0) strengthens above moving average price; +GBX74 [0.6%]

Company Data Report, 2024

Copyright News Bites Pty Ltd Jun 4, 2024

Digital Resources/Online E-Resources

12
AstraZeneca (AZN: GBX12,396.0) in 4th consecutive rise; +GBX50 [0.4%]
Material Type:
Newsletter Article
Add to My Research

AstraZeneca (AZN: GBX12,396.0) in 4th consecutive rise; +GBX50 [0.4%]

Company Data Report, 2024

Copyright News Bites Pty Ltd Jun 4, 2024

Digital Resources/Online E-Resources

13
AstraZeneca (AZN: GBX12,420.0) lifts 0.6% against the trend; +GBX74 [0.6%]
Material Type:
Newsletter Article
Add to My Research

AstraZeneca (AZN: GBX12,420.0) lifts 0.6% against the trend; +GBX74 [0.6%]

Company Data Report, 2024

Copyright News Bites Pty Ltd Jun 4, 2024

Digital Resources/Online E-Resources

14
AstraZeneca (AZN: GBX12,396.0) increases GBX50.0, lifts 3.1% for week; +GBX50 [0.4%]
Material Type:
Newsletter Article
Add to My Research

AstraZeneca (AZN: GBX12,396.0) increases GBX50.0, lifts 3.1% for week; +GBX50 [0.4%]

Company Data Report, 2024

Copyright News Bites Pty Ltd Jun 4, 2024

Digital Resources/Online E-Resources

15
Ventricular Assist Device (VAD) Market Expected to Reach USD 3.08 Bn by 2032: The global ventricular assist device (VAD) market is calculated at USD 1.66 billion in 2024 and is expected to reach around USD 3.08 billion by 2032, growing at a solid CAGR of 7.1% from 2024 to 2032
Material Type:
Newsletter Article
Add to My Research

Ventricular Assist Device (VAD) Market Expected to Reach USD 3.08 Bn by 2032: The global ventricular assist device (VAD) market is calculated at USD 1.66 billion in 2024 and is expected to reach around USD 3.08 billion by 2032, growing at a solid CAGR of 7.1% from 2024 to 2032

NASDAQ OMX's News Release Distribution Channel, 2024

GlobeNewswire, Inc.

Digital Resources/Online E-Resources

16
AstraZeneca (AZN: GBX12,210.0) strengthens above moving average price; +GBX20 [0.2%] Vol Index 1.8 [1 is avg]
Material Type:
Newsletter Article
Add to My Research

AstraZeneca (AZN: GBX12,210.0) strengthens above moving average price; +GBX20 [0.2%] Vol Index 1.8 [1 is avg]

Company Data Report, 2024

Copyright News Bites Pty Ltd Jun 3, 2024

Digital Resources/Online E-Resources

17
Monthly: Lexicon Pharmaceuticals (LXRX: $1.70) gains 10%, beating 87% of stocks
Material Type:
Newsletter Article
Add to My Research

Monthly: Lexicon Pharmaceuticals (LXRX: $1.70) gains 10%, beating 87% of stocks

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd Jun 3, 2024

Digital Resources/Online E-Resources

18
Weekly: Lexicon Pharmaceuticals (LXRX: $1.70) climbs 6% on weak volume; +8c [4.9%]
Material Type:
Newsletter Article
Add to My Research

Weekly: Lexicon Pharmaceuticals (LXRX: $1.70) climbs 6% on weak volume; +8c [4.9%]

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd Jun 3, 2024

Digital Resources/Online E-Resources

19
Monthly: SeaStar Medical Holding (ICU: 37.14c) falls a second month, trailing 82% of stocks
Material Type:
Newsletter Article
Add to My Research

Monthly: SeaStar Medical Holding (ICU: 37.14c) falls a second month, trailing 82% of stocks

News Bites US - NASDAQ, 2024

Copyright News Bites Pty Ltd Jun 3, 2024

Digital Resources/Online E-Resources

20
European Journal of Cardiovascular Nursing Issues Research Articles in May 2024 Edition
Material Type:
Newsletter Article
Add to My Research

European Journal of Cardiovascular Nursing Issues Research Articles in May 2024 Edition

Targeted News Service, 2024

Targeted News Service

Digital Resources/Online E-Resources

Results 1 - 20 of 1,691  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To

Searching Remote Databases, Please Wait